JP2013139394A - Energy production promoter and prophylactic agent or improving agent for muscle ache and/or malaise - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an energy production promoter having high safety, capable of being used as food and drink, and having an excellent energy production promoting action.SOLUTION: The energy production promoter contains at least either panaxatriol or panaxadiol and promotes production of at least either adenosine triphosphate or creatine phosphate, and a prophylactic agent or improving agent contains the energy production promoter and prevents or improves either a muscle ache or a malaise.

Description

  The present invention relates to an energy production promoter, and a preventive or ameliorating agent for at least one of muscle pain and fatigue containing the energy production promoter.

  A cell that is a constituent unit of a living body has functions such as proliferation, metabolism, and repair, and thereby maintains various functions of the living body. The decrease in function in the cells is caused by aging and the like. For example, in many tissues such as the brain, skin, viscera, and bones of the elderly, degenerative atrophy occurs, the number of cells in the tissue decreases, and the physiological function also decreases. Such a decrease in the function of the cells causes various diseases.

Adenosine triphosphate (hereinafter sometimes referred to as “ATP”), which is an energy source, plays an important role for the cells to exert the above functions. ATP is a chemical substance that exists in all cells of the living body and controls its life activity, and is involved in many energy metabolisms. For example, ATP functions as an important energy source in various in vivo reactions such as sugar metabolism, nucleic acid and protein biosynthesis, active transport of ions and the like, and muscle contraction.
Therefore, activation of cell functions such as cell proliferation, metabolism, repair, etc., and anti-aging are promoted by promoting ATP production and replenishing ATP to cells regardless of exercise, even at rest in daily life. The effect of (anti-aging) can be expected.

  In tissue units, particularly large amounts of ATP are utilized in skeletal muscle. Skeletal muscle contains a large amount of a compound called creatine. Creatine is synthesized in vivo from arginine and glycine, and most of them are present in the form of creatine phosphate in skeletal muscle, which receives a phosphate group from ATP by creatine kinase. Creatine phosphate plays an important role in storing high-energy phosphate bonds in cells that consume a large amount of energy, such as muscle, and is particularly useful for ATP during muscle contraction under anaerobic conditions such as exercise. And reverts to creatine at the same time, or becomes creatinine by a non-enzymatic reaction and is excreted in the urine.

Creatine in the body can be increased by ingesting creatine present in meat, etc., but as a method for further increasing creatine, for example, anaerobic solution by rapid contraction for the purpose of enhancing anaerobic exercise capacity. A method of administering creatine together with β-alanine, which is a precursor of β-alanyl histidine dipeptide found in muscle where sugar occurs, has been disclosed (see Patent Document 1). Moreover, a method of administering creatine together with a pentose sugar that is an ATP precursor for the purpose of increasing an energy level (for example, intracellular ATP concentration) has been disclosed (see Patent Document 2). As described above, in order to increase creatine in the living body, it is common to directly take creatine. For example, various supplements for athletes who require instantaneous power are commercially available. .
However, the amount of creatine that can be retained in the body is limited by the amount of muscle, so even if it is consumed, not all creatine is converted into the form of creatine phosphate and used. In addition, creatine that has not been used is filtered by the kidney glomeruli, but there is a problem that it is difficult to be excreted by being reabsorbed by the tubules. Furthermore, when creatine is consumed in excess, the concentration of creatinine, which is a decomposition product thereof, increases excessively in plasma, which causes a problem that the kidneys and the heart are loaded.
Therefore, there is a problem that creatine intake by supplements must be performed with sufficient care and control.

  Therefore, there is a need for a method that is different from the conventional method of supplementing raw materials for energy production (ATP, creatine, etc.) and that can promote energy production even at rest in daily life regardless of exercise. This is the current situation.

Special Table 2000-516464 JP-T-2002-518321

  An object of the present invention is to solve the above-described problems and achieve the following objects. That is, an object of the present invention is to provide an energy production promoter that has high safety, can be used as a food and drink, and has an excellent energy production promoting action.

  In order to solve the above-mentioned problems, the present inventors have made extensive studies and as a result, obtained the following findings. That is, the conventional energy production promoter that contains at least one of panaxatriol and panaxadiol and promotes the production of at least one of adenosine triphosphate and creatine phosphate supplements the raw material for energy production. Unlike the method, since the energy production action inherent in the living body can be promoted, it has been found that energy production can be promoted safely without fear of reducing kidney function, and the present invention has been completed. .

The present invention is based on the above findings by the present inventors, and means for solving the above problems are as follows. That is,
<1> An energy production promoter characterized by containing at least one of panaxatriol and panaxadiol and promoting production of at least one of adenosine triphosphate and creatine phosphate.
<2> The energy production promoter according to <1>, wherein at least one of panaxatriol and panaxadiol is sapogenin derived from ginseng ginseng.
<3> The energy production according to the above <2>, wherein the sapogenin derived from the ginseng ginseng is obtained by hydrolyzing the ginseng ginseng in the presence of an acid aqueous solution of 0.01 mol / L to 4 mol / L and a lower alcohol. It is an accelerator.
<4> A prophylactic or improving agent comprising the energy production promoter according to any one of <1> to <3>, which prevents or ameliorates at least one of muscle pain and fatigue. is there.

<5> An adenosine triphosphate production promoter containing at least one of panaxatriol and panaxadiol and promoting production of adenosine triphosphate.
<6> A creatine phosphate production promoter characterized by containing at least one of panaxatriol and panaxadiol and promoting the production of creatine phosphate.
<7> A food or drink comprising the energy production promoter according to any one of <1> to <3>.

  According to the present invention, there is provided an energy production promoter capable of solving the above-described problems and achieving the above-described object, having high safety, being usable as a food and drink, and having an excellent energy production promoting action. can do.

FIG. 1 is a diagram showing the expression level of ATP in the cypress muscle and liver. FIG. 2 is a diagram showing the expression level of creatine phosphate in the hyfuku muscle.

(Energy production promoter)
The energy production promoter of the present invention contains at least one of panaxatriol and panaxadiol, and further contains other components as necessary.

<Panaxatriol, Panaxadiol>
The panaxatriol (hereinafter sometimes abbreviated as “PT”) and the panaxadiol (hereinafter sometimes abbreviated as “PD”) are compounds belonging to danmaran triterpenes.

  There is no restriction | limiting in particular as content of at least one of said PT and said PD in the said energy production promoter, According to the objective, it can select suitably.

The method for obtaining PT and / or PD is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a plant containing saponin (hereinafter sometimes referred to as “saponin-containing plant”). The method of extracting from, the method of synthesize | combining, the method of using a commercial item etc. are mentioned.
Among these, a method obtained from a saponin-containing plant is preferable in that the PT and / or PD can be obtained with safety. When the PT and / or PD is obtained from the saponin-containing plant, the PT and / or PD is obtained as an aglycon body (sapogenin) in which sugar is detached from the plant-derived saponin (glycoside) and the side chain is closed.

  The method for obtaining the PT and / or PD from the saponin-containing plant is not particularly limited and may be appropriately selected depending on the intended purpose. The saponin-containing plant is allowed to act on an acid aqueous solution having a predetermined concentration. After subjecting to hydrolysis treatment (hereinafter sometimes referred to as “hydrolysis treatment step”), the resulting hydrolyzed solution is neutralized (hereinafter also referred to as “neutralization step”). The residue is dried (hereinafter sometimes referred to as “drying step”) and purified from the residue (hereinafter referred to as “purification step”). This method is more preferable in that it can extract a large amount of the PT and / or PD and can be easily produced.

<< Hydrolysis treatment process >>
The hydrolysis treatment step is a step in which an acid aqueous solution having a predetermined concentration is allowed to act on the saponin-containing plant to hydrolyze the saponin in the plant to produce the PT and / or the PD. The hydrolysis treatment step is preferably performed in the presence of a lower alcohol.

-Saponin-containing plants-
Examples of the saponin-containing plants, if a natural product that contains saponins is not particularly limited and may be appropriately selected depending on the purpose, for example, Araliaceae (Araliaceae), Umbelliferae (Apiaceae), Polygalaceae ( Polygalaceae), bellflower family (Campanulaceae), Cucurbitaceae (Cucurbitaceae), legumes (Fabaceae), Amaranthaceae (Amaranthaceae), lardizabalaceae (lardizabalaceae), rhamnaceae (Rhamnaceae), Liliaceae (Liliaceae), dioscoreaceae (Dioscoreaceae) Plants belonging to These may be used alone or in combination of two or more.

Specific examples include Araliaceae ( Aralia ) (Taranoki, Udo, etc.), Uragi ( Eleutherococcus ) (Ezoukogi, Ukogi, Koshibura, etc.), Tochibaninjin ( Panax ) [American ginseng, Panax ginseng, Sancynin ginseng 7 ginseng), Tochibaninjin (Bamboo ginseng), etc.]; Ceratoceae ( Bupleurum ) [Firefly, Mishimasaiko, etc.]; Himehagi ( Polygala ) [Himehagi, Itohimehagi (Onji), Hirohasenega, etc.] ; bellflower family Campanulaceae genus (platycodon) [bellflower, etc.]; Cucurbitaceae Gynostemma pentaphyllum genus (Gynostemma) [Gynostemma pentaphyllum, etc.]; leguminous Glycyrrhiza (Glycyrrhiza) [licorice, etc.]; specific Yu family Achyranthes bidentata genus (Achyranthes) [Hinata Achyranthes bidentata (Goshitsu), etc.]; lardizabalaceae of Akebia genus (Akebia) [Mitsubaakebi (Mokutsuu), etc.]; rhamnaceae jujuba genus (Ziziphus) [Natsume (gymnastics), etc.]; lily Examples include Ophiopogon of the family [ Dioscorea , etc.]; Dioscorea [ Dioscorea ], etc.

  There is no restriction | limiting in particular as a site | part of the said saponin containing plant, According to the objective, it can select suitably, For example, a root, a rhizome, a leaf, a stem, a flower etc. are mentioned. Specific examples include: ginseng root, ginseng root, tochibanin ginseng root, sorghum root, arachnid root, udo root, mishima psyche root, himehimehagi root, hirohasenega root, kikyo root, amacha eel all Examples include grass, licorice root, chickweed root, honey bee stalk, jujube fruit, genus rhizome, jade beard root, onidokoro rhizome.

  Among these, the saponin-containing plant is preferably ginseng, ginseng root, ginseng root, root ginseng root, ginseng root ginseng root, sorghum root ginseng root, More preferably, the roots of the araliaceae genus taranoki, the roots of the arachnaceae genus genus genus, the whole plant of the cucurbitaceae genus genus amachazuru, and the highest yield of the above-mentioned PT and / or the above-mentioned PD is obtained. The root is particularly preferred.

  The saponin-containing plant may be used as it is collected from nature, for example, by using it after pretreatment appropriately combining washing, drying, cutting, crushing, pulverization, etc. It becomes possible to perform the hydrolysis treatment described later more efficiently. Among these, it is preferable to use a pulverized powdery plant as the saponin-containing plant. In addition, you may utilize a commercial item for the said saponin containing plant. Specific examples of the commercially available products include rice ginseng powder, rice ginseng water extract extract powder (both manufactured by Matsuura Pharmaceutical Co., Ltd.), and the like.

--Aqueous acid solution--
The aqueous acid solution is not particularly limited as long as it is an aqueous solution containing an acid, and can be appropriately selected according to the purpose. For example, an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, or nitric acid is preferable. These may be used alone or in combination of two or more. Among these, an aqueous solution containing hydrochloric acid is more preferable.

  There is no restriction | limiting in particular as the density | concentration of the acid in the said acid aqueous solution, Although it can select suitably according to the objective, 0.01 mol / L-4 mol / L are preferable, and 0.5 mol / L-3 mol / L are more preferable. If the acid concentration is less than 0.01 mol / L, hydrolysis may be insufficient and the PT and / or PD may not be efficiently produced. If the concentration exceeds 4 mol / L, hydrolysis proceeds excessively. And it may be disadvantageous in terms of cost. On the other hand, when the concentration of the acid is within the preferable range, the PT and / or the PD can be efficiently generated by sufficient hydrolysis.

  There is no restriction | limiting in particular as the usage-amount of the said acid aqueous solution, Although it can select suitably according to the objective, It is preferable to use 2 to 20 times volume with respect to the said saponin containing plant. When the amount of the acid aqueous solution used is less than twice the capacity of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction may become saturated and disadvantageous in cost.

-Lower alcohol-
The hydrolysis treatment is more preferably performed in the presence of a lower alcohol. By using a lower alcohol in the hydrolysis treatment step, it is possible to improve the affinity between the saponin-containing plant and the acid aqueous solution, and to proceed the hydrolysis efficiently. In addition, the use of the lower alcohol is advantageous in that the taste and handleability of the obtained PT and / or PD can be improved.

  There is no restriction | limiting in particular as said lower alcohol, According to the objective, it can select suitably, For example, C1-C5 alcohol etc. are mentioned. These may be used alone or in combination of two or more. Among these, methanol, ethanol, and propanol are preferable, and ethanol is particularly preferable from the viewpoint of safety.

  When the lower alcohol is used as an aqueous solution containing the lower alcohol, the mixing ratio of water and the lower alcohol is not particularly limited and may be appropriately selected depending on the intended purpose. The lower alcohol is preferably 9: 1 to 2: 1 and more preferably 3: 1.

There is no restriction | limiting in particular as the usage-amount of the said lower alcohol, Although it can select suitably according to the objective, 1 volume%-80 volume% are preferable with respect to the total amount of a hydrolysis liquid, 10 volume%-50 volume % Is more preferable, and 20% by volume to 40% by volume is particularly preferable. When the amount of the lower alcohol used is less than 1% by volume with respect to the total amount of the hydrolyzed liquid, the PT and / or the PD may not be efficiently produced. The PT and / or the PD may not be generated efficiently or may be disadvantageous in cost. On the other hand, when the amount of the lower alcohol used is within the particularly preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.
The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the acid aqueous solution and the lower alcohol.

  The total amount of the reaction solution including the acid aqueous solution and the lower alcohol (total amount of hydrolyzed solution) is preferably 2 to 20 times the volume of the saponin-containing plant. When the total reaction liquid amount is less than 2 times the volume of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction can become saturated and costly.

  There is no restriction | limiting in particular as processing temperature in the said hydrolysis process, Although it can select suitably according to the objective, 60 to 100 degreeC is preferable and 70 to 90 degreeC is more preferable. If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient and the PT and / or PD may not be produced efficiently. If the treatment temperature exceeds 100 ° C, special production equipment is required. , May be disadvantageous in cost. On the other hand, when the treatment temperature is within the more preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.

  There is no restriction | limiting in particular as processing time in the said hydrolysis process, Although it can select suitably according to the objective, 30 minutes-24 hours are preferable, and 2 hours-8 hours are more preferable. If the treatment time is less than 30 minutes, hydrolysis may be insufficient and the PT and / or PD may not be efficiently produced. If the treatment time exceeds 24 hours, the reaction may proceed excessively, It may be disadvantageous in cost. On the other hand, when the processing time is within the more preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.

<< Neutralization process >>
The neutralization step is a step of neutralizing the hydrolyzed liquid obtained in the hydrolysis treatment step.
The neutralization method is not particularly limited and may be appropriately selected from known methods according to the purpose. For example, the hydrolyzed solution may contain sodium hydroxide, potassium hydroxide, or the like. It can be carried out by appropriately adding a strong base aqueous solution.
The pH after neutralization is not particularly limited as long as it is neutral, and can be appropriately selected according to the purpose, but is preferably 5 to 8.

<< Filtration process >>
The said filtration process is a process of filtering the liquid after the hydrolysis process after neutralizing in the said neutralization process, and isolate | separating into a filtrate and a residue.
There is no restriction | limiting in particular as said filtration method, According to the objective, it can select suitably from well-known methods. After filtration, washing with water may be repeated until there is no more salt. The washing with water is also preferable in that the alcohol concentration can be lowered.

-Hydrofiltration-
When the lower alcohol is not used in the hydrolysis treatment step, the neutralization can proceed to the filtration step as it is, but when the lower alcohol is used, the produced PT and / or before filtration. Alternatively, for the purpose of promoting the residue of the PD in the residue, it is preferable to add water to lower the lower alcohol concentration in the solution after the hydrolysis treatment.

  In this case, the amount of water to be added is preferably as large as possible, but the lower alcohol concentration in the solution after the hydrolysis treatment is preferably as low as possible. Specifically, it is preferably added so as to be 50% by volume or less. It is more preferable to add so that it may become 10% or less, and it is especially preferable to add so that it may become 10 volume% or less. If the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, the produced PT and / or PD is dissolved in the lower alcohol and discharged as a filtrate, and the residue The content of the PT and / or the PD may be reduced. On the other hand, when the lower alcohol concentration in the liquid after the hydrolysis treatment is within the particularly preferable range, it is advantageous in that the content of the PT and / or the PD in the residue can be further increased.

-Filtration after concentration under reduced pressure-
Moreover, the lower alcohol concentration in the liquid after the hydrolysis treatment is lowered by distilling off the lower alcohol by vacuum concentration for the purpose of promoting the residual PT and / or PD produced in the residue before filtration. be able to.

  In this case, there is no restriction | limiting in particular as concentration temperature, Although it can select suitably according to the objective, 70 degrees C or less is preferable and 40 to 50 degreeC is more preferable.

  The concentration of the lower alcohol after concentration under reduced pressure is not particularly limited and may be appropriately selected depending on the intended purpose. It is preferably distilled off so as to be 50% by volume or less, and preferably 30% by volume or less. More preferably, it is more preferably distilled off to 10% by volume or less. If the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, the produced PT and / or PD is dissolved in the lower alcohol and discharged as a filtrate, and the residue This is disadvantageous in that the content of the PT and / or the PD is reduced. On the other hand, when the lower alcohol concentration in the solution after the hydrolysis treatment is within the particularly preferable range, it is advantageous in that the content of the PT and / or the PD in the residue can be further increased.

  Moreover, although the said vacuum concentration and the said hydrofiltration may each be performed as a single process, you may perform as a series of processes. In this case, water is added to the liquid after concentration under reduced pressure, and the hydrofiltration is performed.

<< Drying process >>
The said drying process is a process of drying the residue after the said filtration process, and obtaining the dried material containing the said PT and / or the said PD.
The method for performing the drying is not particularly limited and can be appropriately selected from known methods according to the purpose. Examples thereof include a freeze-drying method, a ventilation drying method, a heat drying method, and a vacuum drying method. It is done.

<< Purification process >>
The purification step includes the PT and / or the hydrolyzed product obtained in the hydrolysis treatment step, preferably the residue produced through the neutralization step, the filtration step, and / or the drying step. This is a step of purifying the PD.
The purification method is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a purification method using a silica gel column. There is no restriction | limiting in particular as a method refine | purifying using the said silica gel column, According to the objective, it can select suitably, For example, the ethanol solution containing 1 mass%-5 mass% of the processed material obtained by acid hydrolysis Next, after removing insolubles using a filter paper or a centrifuge, it was further concentrated 5 to 10 times using a rotary evaporator and filled with silica gel (for example, silica gel 60N manufactured by Kanto Chemical Co., Inc.). Examples include a method in which the concentrated solution is added to a glass column and column separation is performed using chloroform: ethanol = 10: 1 (V / V) as an eluent.
On normal phase TLC using chloroform: ethanol = 10: 1 (V / V) as a developing solvent, a fraction corresponding to an Rf value of 0.4 was concentrated to obtain highly pure panaxatriol (PT). The fraction corresponding to the Rf value of 0.6 can be concentrated to obtain highly pure panaxadiol (PD).

<Other ingredients>
The other components in the energy production promoter are not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose. Examples thereof include additives, adjuvants, and water. It is done.

  The additive or the adjuvant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include bactericides, preservatives, binders, thickeners, fixing agents, binders, and coloring agents. , Stabilizers, pH adjusters, buffers, isotonic agents, solvents, antioxidants, UV inhibitors, crystal precipitation inhibitors, antifoaming agents, physical property improvers, preservatives, vitamins, amino acids, fragrances Etc. These may be used alone or in combination of two or more.

  There is no restriction | limiting in particular as said disinfectant, According to the objective, it can select suitably, For example, cationic surfactants, such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, etc. are mentioned.

  There is no restriction | limiting in particular as said preservative, According to the objective, it can select suitably, For example, paraoxybenzoic acid esters, chlorobutanol, cresol, etc. are mentioned.

  The binder, thickener, and fixing agent are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include starch, dextrin, maltitol, cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, and hydroxyethylcellulose. , Hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethyl starch, pullulan, sodium alginate, ammonium alginate, propylene glycol ester alginate, guar gum, locust bean gum, gum arabic, xanthan gum, gelatin, casein, polyvinyl alcohol, polyethylene oxide, polyethylene glycol, Ethylene / propylene block polymer, sodium polyacrylate, sodium lauryl sulfate, polyethylene And vinyl pyrrolidone.

  The binder is not particularly limited and may be appropriately selected depending on the intended purpose. For example, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, hydroxy Examples include propyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate, calcium carbonate, calcium stearate, polyvinyl pyrrolidone, and stearic acid monoglyceride.

  The colorant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include titanium oxide and iron oxide.

  The stabilizer is not particularly limited and may be appropriately selected depending on the intended purpose. For example, tragacanth, gum arabic, agar, gelatin, sodium pyrosulfite, EDTA (ethylenediaminetetraacetic acid), thioglycolic acid, thiol Examples include lactic acid.

  There is no restriction | limiting in particular as said pH adjuster and said buffering agent, According to the objective, it can select suitably, For example, sodium citrate, sodium acetate, sodium phosphate, sodium hydrogencarbonate etc. are mentioned.

  The tonicity agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include sodium chloride and glucose.

  There is no restriction | limiting in particular as content of the said other component in the said energy production promoter, According to the objective, it can select suitably.

<Application>
Since the energy production promoter has an excellent energy production promoting action with respect to the energy production action originally possessed by the living body, there is no risk of reducing kidney function, and it can be safely ingested as a food and drink. In particular, it is suitably used for enhancing the exercise ability of muscles and other tissues, and for preventing or improving muscle pain associated with labor and exercise, general malaise, and the like.
In addition, the energy production promoter can promote the production of energy even in tissues such as skeletal muscles, and thus is effective in preventing or improving wrinkles, swelling, sagging, etc. in skin tissues.
Since the energy production promoter has an excellent adenosine triphosphate production promoting action, it can be suitably used as an adenosine triphosphate production promoter. Moreover, since the said energy production promoter has the production promotion effect | action of the outstanding creatine phosphate, it can utilize suitably also as a creatine phosphate production promoter.

(Preventive or improving agent)
The preventive agent or the improving agent of the present invention contains the energy production promoter of the present invention as an active ingredient, and further contains other components as necessary. The preventive agent or ameliorating agent has an excellent energy production promoting action, so that it increases the exercise capacity of muscles and other tissues on a daily basis, and prevents or improves muscle pain associated with labor and exercise, general malaise, etc. Is preferably used. Moreover, since the said energy production promoter contains PT and / or PD derived from the ginseng ginseng, since it is derived from natural products, it is advantageous in that it has no side effects and is highly safe.

  The content of the energy production promoter in the preventive agent or improver is not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose. The preventive agent or improver may be the energy production promoter itself.

The other component in the preventive agent or improver is not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose. For example, the other component in the energy production promoter And the like.
There is no restriction | limiting in particular also as content of the said other component, According to the objective, it can select suitably.

<Dosage form>
There is no restriction | limiting in particular as a dosage form of the said energy production promoter and the said preventive agent or an improving agent, According to the objective, it can select suitably, For example, an oral solid agent, an oral semi-solid agent, an oral liquid agent, etc. Is mentioned. Among these, since PT and PD have a bitter taste, oral solid preparations are preferable.

-Oral solid agent-
The oral solid preparation is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include tablets, coated tablets, granules, powders, capsules, troches, tablets and the like.
The method for producing the oral solid preparation is not particularly limited, and a conventional method can be used. For example, the PT and / or the PD, or the energy production promoter, and if necessary, the other It can manufacture by adding the component of.

-Oral semi-solid formulation-
The oral half-solid preparation is not particularly limited as long as it is located between the liquid preparation and the solid preparation, and can be appropriately selected according to the purpose. For example, a lozenge, chewing gum, whipping agent, jelly Agents and the like.
The method for producing the oral semi-solid preparation is not particularly limited, and a conventional method can be used. For example, the PT and / or the PD, or the energy production promoter, if necessary, It can be produced by adding other components.

-Oral solution-
There is no restriction | limiting in particular as said oral liquid agent, According to the objective, it can select suitably, For example, an internal use liquid agent, a syrup agent, an elixir etc. are mentioned.
There is no restriction | limiting in particular as a manufacturing method of the said oral liquid preparation, A normal method can be used, for example, said PT and / or said PD, or the said energy production promoter, and other said other as needed. It can be produced by adding ingredients.

<Food &Drink>
When the energy production promoter and the preventive agent or improver are ingested as food or drink, the food or drink may be the energy production promoter itself or may be mixed with other foods. Good.
In the present invention, the food and drink are those that are less likely to harm human health and are taken by oral or gastrointestinal administration in normal social life. It is not limited to categories such as quasi-drugs, and includes, for example, a wide range of foods that are taken orally, such as general foods, health foods, health functional foods, quasi drugs, and pharmaceuticals.

  When the said energy production promoter in the said food-drinks and the said preventive agent or improving agent are what was mixed with other foodstuffs, there is no restriction | limiting in particular as the compounding quantity, The effect of this invention is not impaired. Within the range, it can mix | blend suitably according to the kind of food / beverage products used as object.

  There is no restriction | limiting in particular as said kind of food / beverage products, It can select suitably according to the objective, For example, drinks, such as a soft drink, a carbonated drink, a nutrition drink, a fruit drink, a lactic acid drink; Ice cream, ice sherbet, Frozen desserts such as shaved ice; noodles such as buckwheat, udon, harusame, dumpling skin, shumai skin, Chinese noodles, instant noodles; rice cakes, candy, gum, chocolate, tablet confectionery, snacks, biscuits, jelly, jam, cream, baked Sweets such as confectionery and bread; crab, salmon, clams, tuna, sardines, shrimp, skipjack, mackerel, whale, oyster, saury, squid, red scallop, scallop, abalone, sea urchin, salmon roe, tocobushi, etc .; Processed fishery and livestock products such as sausages; dairy products such as processed milk and fermented milk; salad oil, tempura oil, margarine, mayonnaise, short Oils and processed foods such as sauces, sauces, sauces, sauces, etc .; curry, stew, oyakodon, rice cakes, miso cooked, Chinese rice cakes, and rice cakes, tempura, rice cakes, coconut rice, oden, marvodorf Retort pouch foods such as beef bowl, meat sauce, egg soup, omelet rice, dumplings, shumai, hamburger, meatballs; various forms of health foods, nutritional supplements, pharmaceuticals, quasi drugs, and the like.

<Ingestion>
There is no restriction | limiting in particular as an ingestion method of the said energy production promoter and the said preventive agent or an improving agent, intake amount, the frequency | count of ingestion, ingestion time, and ingestion object, According to the objective, it can select suitably.
There is no restriction | limiting in particular as said ingestion method, Although it can select suitably according to the objective, The method of ingesting orally is preferable at the point which can be ingested easily and is easy to ingest continuously.
The intake amount is not particularly limited and may be appropriately selected in consideration of various factors such as the age, weight, constitution, symptom, and presence / absence of administration of a drug containing another component as an active ingredient. it can.
The animal species to be ingested are those that are suitably applied to humans, but as long as the effects are exerted, animals other than humans, such as mice, rats, hamsters, birds, dogs, It is also possible to apply to cats, sheep, goats, cows, pigs, monkeys and the like.

  EXAMPLES The present invention will be specifically described below with reference to examples of the present invention, but the present invention is not limited to these examples.

(Production Example 1)
<Preparation of processed ginseng acid products>
1 kg of ginseng powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) is suspended in 10 L of 25 wt% aqueous ethanol solution containing 5.9 wt% hydrochloric acid (2 mol / L hydrochloric acid) and reacted at 80 ° C. for 6 hours with slow stirring. I let you. Subsequently, after cooling this reaction liquid on ice, 5 mol / L sodium hydroxide aqueous solution was added and it adjusted to pH 7.0. Next, the pH-adjusted solution was diluted 10-fold with distilled water, suction filtered, and separated into a filtrate and a residue. The obtained residue was freeze-dried to obtain 180 g of a ginseng treated product.
When the contents of panaxatriol (PT) and panaxadiol (PD) in the obtained processed ginseng acid product were measured by the following method, PT was 5.0% by mass, and PD was It was 5.5% by mass.

-Analysis of PT and PD-
About 0.1 g of the seven ginseng acid treated products were accurately weighed, added with about 8 mL of ethanol (purity 99.5% by volume), and suspended in an ultrasonic bath for 15 minutes. After centrifugation at about 700 × g for 10 minutes, ethanol (purity 99.5% by volume) was added to the supernatant to make exactly 10 mL. This liquid was measured by gas chromatography under the following conditions. The PT holding time under the following conditions was about 29 minutes, and the PD holding time was about 18 minutes.
[Analysis conditions]
Gas chromatograph: GC353B (GL Science Co., Ltd.)
Detector: Hydrogen flame ionization detector (FID)
Injection method: Split injection method (split ratio 1:50)
Column: DB-17MS (length 30 m, inner diameter 0.25 mm, film thickness 0.25 μm, manufactured by Agilent Technologies)
Column temperature: Initial temperature: 310 ° C
Initial temperature holding time: 20 minutes
Temperature increase rate: 10 ° C / min
Achieving temperature: 320 ° C
Achieving temperature holding time: 14 minutes Carrier gas: Helium Flow rate: 1.5 mL / min Inlet temperature: 320 ° C
Detector temperature: 320 ° C
Injection volume: 1 μL

  Panaxatriol standard product (manufactured by LKT Laboratories) and panaxadiol standard product (manufactured by LKT Laboratories) were prepared to 1 mg / mL, 0.5 mg / mL, and 0.1 mg / mL, respectively, and a calibration curve was prepared. A standard solution was prepared. The standard solution for calibration curve was measured by gas chromatography under the same conditions as described above using 1 μL each. Each peak area was measured, and a calibration curve was prepared from the peak area and concentration of each standard curve standard solution. Using this calibration curve, the contents of PT and PD in the processed ginseng acid product were measured.

<Separation of Panaxatriol (PT) and Panaxadiol (PD)>
An ethanol solution containing 3% by mass of the processed ginseng acid was prepared. Next, after removing insolubles using filter paper, the solution is further concentrated 8 times using a rotary evaporator, and the concentrated solution is added to a glass column packed with silica gel (silica gel 60N, manufactured by Kanto Chemical Co., Inc.), Column fractionation was performed using chloroform: ethanol = 10: 1 (V / V) as an eluent. On normal phase TLC using chloroform: ethanol = 10: 1 (V / V) as a developing solvent, the fraction corresponding to an Rf value of 0.4 was concentrated to obtain highly pure panaxatriol (PT). It was. Further, the fraction corresponding to an Rf value of 0.6 was concentrated to obtain highly pure panaxadiol (PD).

Example 1
A mixed diet containing 1% by mass of the processed ginseng acid product produced in Production Example 1 was prepared in a high fat diet (QuickFat, manufactured by Clea Japan Co., Ltd.). KK-A ^y / TaJc1 mice (4 weeks old, male, n = 3, obtained from Clea Japan Co., Ltd.) which had been preliminarily raised for 5 days were allowed to freely ingest for 7 days (hereinafter referred to as “Tanachi ginseng acid treated product administration”). Sometimes referred to as a group). At this time, water was also given freely.

(Example 2)
A mixed diet containing 0.1% by mass of panaxatriol separated and purified in Production Example 1 was prepared in a high fat diet (QuickFat, manufactured by CLEA Japan, Inc.). KK-A ^y / TaJc1 mice (4 weeks old, male, n = 3, obtained from Clea Japan Co., Ltd.) which had been preliminarily raised for 5 days were freely ingested for 7 days (hereinafter referred to as “PT administration group”) Is). At this time, water was also given freely.

(Example 3)
A mixed diet containing 0.1% by mass of panaxadiol separated and purified in Production Example 1 was prepared in a high fat diet (QuickFat, manufactured by CLEA Japan, Inc.). KK-A ^y / TaJc1 mice (4 weeks old, male, n = 3, obtained from Clea Japan Co., Ltd.) which had been preliminarily raised for 5 days were freely ingested for 7 days (hereinafter referred to as “PD administration group”). Is). At this time, water was also given freely.

(Comparative Example 1)
A high-fat diet (QuickFat, manufactured by Clea Japan Co., Ltd.) was freely ingested for 7 days by KK-A ^y / TaJc1 mice (5 weeks old, male, n = 3, obtained from Clea Japan Co., Ltd.) that had been bred for 5 days. (Hereinafter sometimes referred to as “control group”). At this time, water was also given freely.

(Test Example 1)
<ATP and creatine phosphate analysis in liver and hyfuku muscle>
-Preparation of measurement sample-
The livers and cypress muscles (skeletal muscles) of mice after 7 days of Examples 1 to 3 and Comparative Example 1 were collected and their masses were measured. Next, each collected liver or cypress muscle is placed in a crushing tube, and a methanol solution containing 50 μM of an internal standard substance (D-Camphor-10-sulfonic Acid Sodium Salt (CSA), manufactured by Wako Pure Chemical Industries, Ltd.). Add 600 μL, freeze with liquid nitrogen, and crush five times using a bead type cell crusher (MS-100R, manufactured by Tommy Seiko Co., Ltd.) at 4,000 rpm for 60 seconds to prepare a crush solution did.

  Next, 600 μL of chloroform and 240 μL of Milli-Q water were added to the crushed liquid and stirred, followed by centrifugation under conditions of 2,300 × g, 4 ° C., and 5 minutes. After centrifugation, 240 μL each of the aqueous phase was transferred to two ultrafiltration tubes (Ultrafree (registered trademark) -MC, UFC3 LCC, centrifugal filter unit 5 KDa, manufactured by Millipore). This was centrifuged at 9,100 × g, 4 ° C. for 120 minutes and subjected to ultrafiltration treatment. The obtained filtrate was dried and dissolved again in 50 μL of Milli-Q water. Further, using Milli-Q water, the liver sample was diluted 5 times, and the fibroid muscle sample was diluted 10 times, and used as a measurement sample of a capillary electrophoresis-time-of-flight mass spectrometer (CE-TOFMS).

-CE-TOFMS measurement-
Using the measurement sample, measurement was performed in the anion mode of CE-TOFMS under the following conditions.
[Measurement condition]
Apparatus: Agilent CE-TOFMS system (manufactured by Agilent Technologies)
Capillary: Fused silica capillary (G1600-62211, inner diameter: 50 μm, length: 80 cm, manufactured by Agilent Technologies)
Run buffer: Anion Buffer Solution (p / n: H3302-1021) (manufactured by Agilent Technologies)
Rinse buffer: Anion Buffer Solution (p / n: H3302-1022) (manufactured by Agilent Technologies)
Sample introduction: Pressure injection 50 mbar, 25 seconds CE voltage: Positive, 30 kV
MS ionization: ESI Negative
MS capillary voltage: 3,500V
MS scan range: m / z 50-1,000
Sheath liquid: HMT Sheath Liquid (p / n: H3301-1020)

-Data processing-
Peaks detected by CE-TOFMS measurement were automatically extracted using automatic integration software, and mass-to-charge ratio (m / z), peak area value, and migration time (Migration time: MT) were obtained as peak information. The obtained peak area value was converted into a relative area value by the following formula (1), and further converted into a relative value by the following formula (2). In addition, since the obtained data includes adduct ions such as Na ⁺ and K ⁺ and fragment ions such as dehydration and deammonium, these molecular weight-related ions are deleted, and the peak examined is m Based on the values of / z and MT, the peaks between the samples were collated and aligned.
Relative area value = (Area value of peak of measurement sample) / (Area value of peak of internal standard substance × mass of measurement sample) Expression (1)
Relative value = (Relative area value of X) / (Relative area value of Y) (2)
However, in the formula (2), “X relative area value” represents the relative area value of the ginseng treated product administration group, PT administration group, or PD administration group, and “Y relative area value” Represents the relative area value of the control group.

  The result of the relative value calculated by the formula (2) is shown in Table 1 below. Moreover, the result of ATP is shown in FIG. 1, and the result of creatine phosphate is shown in FIG. In Table 1 below, “nd” indicates that it could not be detected.

  From the results shown in Table 1, FIG. 1 and FIG. 2, the group 7 treated with ginseng acid, the PT administration group, and the PD administration group showed a significant increase in the amount of ATP in the cypress muscle and liver compared to the control group. Was recognized. In addition, creatin phosphate was also significantly increased in the hyfuku muscle.

Since the energy production promoter of the present invention has an excellent energy production promoting action with respect to the energy production action originally possessed by the living body, there is no fear of reducing kidney function, and it can be safely ingested as a food or drink. It is preferably used for daily enhancement of exercise capacity of muscles and other tissues, and prevention or improvement of general malaise associated with work and exercise.
In addition, the energy production promoter can promote the production of energy even in tissues such as skeletal muscles, and thus is effective in preventing or improving wrinkles, swelling, sagging, etc. in skin tissues.
Since the energy production promoter has an excellent adenosine triphosphate production promoting action, it can be suitably used as an adenosine triphosphate production promoter. Moreover, since the said energy production promoter has the production promotion effect | action of the outstanding creatine phosphate, it can utilize suitably also as a creatine phosphate production promoter.

Claims (4)

  An energy production promoter characterized by containing at least one of panaxatriol and panaxadiol and promoting production of at least one of adenosine triphosphate and creatine phosphate.   The energy production promoter according to claim 1, wherein at least one of panaxatriol and panaxadiol is a sapogenin derived from ginseng ginseng.   The energy production promoter according to claim 2, wherein the sapogenin derived from the ginseng ginseng is obtained by hydrolyzing the ginseng ginseng in the presence of a 0.01 mol / L to 4 mol / L acid aqueous solution and a lower alcohol.   A preventive or ameliorating agent comprising the energy production promoter according to any one of claims 1 to 3 and preventing or improving at least one of muscle pain and fatigue.